Hemedex Signs Distribution Agreement with Codman
CAMBRIDGE, Mass., April 27 /PRNewswire/ -- Hemedex, Inc., a
privately-held Cambridge, MA medical device company, announced today that
it has reached an agreement with Codman & Shurtleff, Inc. to distribute the
only minimally invasive device that can measure cerebral blood flow and
cerebral tissue perfusion in absolute units, in real time.
Cerebral tissue perfusion, the rate at which blood is
replenished at
the capillary level, is the primary factor in the transport of oxygen and
nutrients to the brain. Adequate cerebral tissue perfusion is an essential
requirement to maintain brain function.
The Hemedex QFlow 500(TM) Perfusion Probe is placed into
targeted
cerebral tissue where it responds rapidly to changes in cerebral perfusion,
allowing clinicians to quickly individualize therapy. The probe is
connected to the Bowman Perfusion Monitor(R) which calculates, stores and
displays the perfusion data.
Clinical data suggests this technology may help doctors
better identify
and manage those patients at risk for complications from stroke, traumatic
brain injury and subarachnoid hemorrhage due to decreased cerebral blood
flow by providing continuous, real-time, soft-tissue perfusion measurements
in absolute units.
"The Hemedex QFlow 500 probe has provided an important
advance in our
neuro monitoring capabilities and has become a highly valuable tool in our
clinical decision making," according to Geoffrey Manley, M.D., PhD, Chief
of Neurotrauma at the San Francisco General Hospital and Medical Center and
Co- Director of the UCSF Brain and Spinal Injury Center (BASIC). "We now
seek to use the Hemedex technology whenever we are treating a severe
traumatic brain injury in our Neuro Intensive Care Unit."
"Codman is a world class company that will be an excellent
partner to
help establish the Hemedex cerebral blood flow monitor as an essential
element of neurosurgery practice by helping surgeons and clinicians
optimize clinical decision making," said H. Frederick Bowman, Ph.D.,
Hemedex Chairman and CEO.
About Codman
Codman & Shurtleff, Inc. develops and markets a wide range of
diagnostic and therapeutic products for the treatment of central nervous
system disorders. The company was founded in 1838 and has established a
strong leadership position within the industry.
About Hemedex
Hemedex, founded in 2000, develops and manufactures devices
that
quantify blood perfusion at the capillary level for applications in a range
of clinical care indications.
Hemedex Inc. to Present at Medtech Insight and Windhover Information's ''Investment In Innovation (In3) WEST'' Conference, February 23-24, 2006, Irvine, CA
IRVINE, Calif.--(BUSINESS WIRE)--Feb. 17,
2006--Hemedex Inc.:
-- Hemedex Inc. has announced that it will be presenting on Friday,
February 24, 2006 at 9:50 am at Medtech Insight and Windhover
Information's "Investment In Innovation (In3) WEST: A Preview of
Early-Stage Medical Technology Companies" Conference, February 23-24,
2006 at the Hyatt Regency Irvine in Irvine, California.~ [Read
the entire release HERE]
Dr. Peter Vajkoczy Presents Latest Data on Bowman Perfusion Monitoring System
CAMBRIDGE, Mass.--(PR News Wire)--October 14, 2005— Dr. Peter Vajkoczy presented his latest patient data using the Bowman Perfusion Monitoring System™ to monitor absolute cerebral blood flow at a reception held by Hemedex™ Inc. of Cambridge, Massachusetts. Dr. Vajkoczy is a faculty member of The University of Heidelberg and member the neurosurgical team at the Mannheim Medical Clinic in Mannheim, Germany. He has accumulated more experience with the Bowman Perfusion Monitoring System than anyone else in the world. His results support the use of the system to alert the medical staff in real time to the occurrence of vasospasm resulting from subarachnoid hemorrhage as well as in guiding the therapy of these patients. Dr. Vajkoczy also presented data demonstrating the benefit of the device in guiding the management of patients with traumatic brain injury. ~ [Read the entire release HERE]
Hemedex Receives FDA Clearance to Market Its Tissue Perfusion Monitor
CAMBRIDGE, Mass.--(BW HealthWire)--June 14, 2002--Hemedex, Inc., announced today that it has received clearance from the U.S. Food and Drug Administration, pursuant to its 510(k) pre-market notification, to market its Bowman Perfusion Monitor(TM), Model 500 in the United States. The Bowman Perfusion Monitor was developed to provide clinicians a powerful prognostic tool by quantifying tissue blood flow in continuous real time, and absolute units. Hemedex, Inc., a privately held company, designs, develops and markets tissue perfusion-measuring devices that address unmet clinical needs in numerous critical medical and surgical situations. The Bowman Perfusion Monitor, Model 500, is the first commercially available device that monitors tissue blood flow continuously at the capillary level in real time and absolute units of ml/100g-min. The Bowman Perfusion Monitor utilizes a proprietary thermal diffusion technology through its minimally-invasive, QFlow 500 Probe, which physicians can implant in any target soft tissue. ~ [Read the entire release HERE]
Hemedex, Inc. Presents Business Update and Corporate Vision at Emerging Medical Technologies - East Conference
CAMBRIDGE, Mass.,
Sept. 11 /PRNewswire/ -- Hemedex, Inc., a privately held company developing
a stream of products to provide clinicians with valuable new prognostic
data by measuring tissue blood flow in multiple clinical application areas,
presented an overview of recent milestones achieved by the Company, and
outlined management's vision for near term development and future strategic
growth, to healthcare industry executives and investors at the recently
held EMT-East Conference. ~ [Read
the entire release HERE]
Hemedex, Inc. Hosts First Tissue
Perfusion Symposium
CAMBRIDGE, Mass.--(BW
Health Wire)--June 5, 2001--Hemedex, Inc., a privately held company developing
a stream of products to provide valuable new prognostic data by measuring
tissue blood flow for multiple clinical application areas, today announced
details from the Company's First Annual Tissue Perfusion Symposium, which
was held at the Boston Cambridge Marriott Hotel in Kendall Square on May
18th-19th. ~ [Read the entire
release HERE]
Hemedex Receives Investment to Develop
Blood Perfusion Measurement Technology; Hanmi Pharmaceuticals. Ltd. Makes
Multimillion Dollar Equity Investment
CAMBRIDGE, Mass. (BW Health Wire) - October 13, 2000 -- Hemedex, Inc., a privately held company developing minimally invasive sensors to measure tissue blood flow, has received a multimillion dollar equity investment from Hanmi Pharmaceuticals, Ltd., of Seoul, Korea. ~ [Read the entire release HERE]
[ TOP ]